Exosomes and PDRN appear increasingly often in hair-treatment descriptions. They may be presented alongside words such as regeneration, renewal, repair or advanced delivery. For someone worried about thinning, that language can make an unfamiliar ingredient sound like the obvious next step.
But a scientific term is not a complete treatment explanation. You still need to know what the product contains, how it is used, what condition it was studied for and whether the evidence matches the service being offered.
The useful question is not simply whether these ingredients are “good for hair.” It is whether a particular product, delivered in a particular way, has convincing evidence for the outcome you want.
Here are seven checks to help you read the claims without dismissing research or accepting promises that go beyond it.
1. Exosomes and PDRN are different things
Exosomes are small extracellular vesicles involved in communication between cells. PDRN, short for polydeoxyribonucleotide, refers to mixtures of DNA fragments. They are not interchangeable names for the same ingredient, and neither term automatically means that a product contains living stem cells.
The distinction is visible in the research itself: studies of an exosome-containing formulation and studies of injected PDRN investigate different materials and protocols. See the exosome-containing formulation trial and the clinical PDRN study.
For a consumer, the next question is basic: what exactly is in the finished product? A treatment name may combine several ingredients, devices and services while highlighting only the most marketable term.
Ask for the product name and an explanation of its intended use. If the answer changes between “exosomes,” “stem cells,” “growth factors” and “PDRN,” ask the provider to separate those descriptions.
You do not need a molecular-biology background to expect a clear answer. A provider should be able to explain what is being applied without relying entirely on an animation or a string of technical words.
2. Delivery method changes the question
A serum placed on intact skin is not the same intervention as an injection. Nor is it automatically equivalent to a product used alongside a procedure that disrupts the skin barrier.
That matters because evidence belongs to a specific intervention. If a study investigated injections, it cannot by itself establish that a cosmetic serum produces the same result. Conversely, tolerability during surface application does not establish the safety of injecting that material.
When comparing exosomes and PDRN services, ask:
- Is the product applied to intact skin?
- Is any device used, and what does it do?
- Does the procedure break the skin?
- Who performs it, and what are their qualifications?
- What aftercare and adverse-effect advice are provided?
The answers should be available before payment. Terms such as “infusion” or “delivery technology” are too vague to replace an explanation of the actual procedure.
Also ask whether the evidence supplied used that same route. A brochure that switches between serum studies and injection studies without explaining the difference leaves an important gap.
The most sophisticated-looking delivery system is not automatically the best choice for your diagnosis or circumstances.
3. Emerging evidence deserves careful reading
There is human research in this area, so it would be inaccurate to say that nothing has been studied. However, promising findings do not establish that all products using the same headline ingredient are effective.
A 2025 pilot randomised trial allocated 24 men to an exosome-containing plant-extract formulation or a control; 20 completed the study. Outcomes were followed over 16 weeks. Its small sample and specific combined formulation limit how broadly the results can be applied. It does not validate every “exosome” service. Read the original trial.
A 2015 PDRN study involved women receiving a course of injections, with one group also receiving platelet-rich plasma. The comparison did not provide the same information as a placebo-controlled trial of a topical consumer serum. Read the original PDRN paper.
When reading claims about exosomes and PDRN, look beyond the headline conclusion. How many participants were studied? What was the comparison? Was the treatment a combination? How long were outcomes followed?
A study can be useful while still leaving major questions unanswered. Acknowledging those limits is part of evaluating evidence properly.
4. Ingredient evidence is not finished-product evidence
Imagine two products sharing one ingredient name. One contains several additional actives and is delivered through a procedure. The other is a rinse-off cosmetic used briefly. Even before considering the results, they are different interventions.
For exosomes and PDRN, ask whether the cited research tested the exact finished product. If not, ask how closely the product and protocol match.
Useful details include the formulation, route, treatment schedule, participant diagnosis and outcome measured. You do not need every manufacturing document, but a provider should explain why the cited evidence is relevant.
Be especially careful with phrases such as “clinically tested ingredient.” That may refer to a supplier study, a laboratory experiment or a different product entirely. Ask what was tested and whether the results were published.
Laboratory findings can help researchers decide what to investigate next. They do not, by themselves, tell you how much visible improvement a person should expect.
The same applies to a mechanism diagram. Showing a proposed biological pathway is different from demonstrating a meaningful outcome in a controlled study. A plausible explanation should lead to a testable claim, not replace the need for one.
5. Singapore regulatory language needs precision
In Singapore, cosmetic products have a defined regulatory scope. They are generally intended for external contact for purposes such as cleaning, protecting or changing appearance. Injected products are not cosmetics. HSA also distinguishes product notification from an endorsement of effectiveness, and cosmetic claims must stay within the permitted scope. Read HSA’s cosmetic-product overview.
This is why “HSA notified” should not be interpreted as “proven to regrow hair.” Ask what the statement actually refers to: the product, a facility, a device or something else.
At the same time, do not assume that every product described with exosomes and PDRN has the same classification. The details matter, including its intended use and how it is administered.
A useful response to an approval claim is: “Can you show me the exact product name and explain what this regulatory status covers?”
If that question cannot be answered clearly, pause the purchase. Regulatory language should make the offering easier to understand, not make ordinary questions feel inappropriate.
Medical-sounding branding does not remove the need for transparent product information or an appropriate assessment.
6. Safety and suitability require more than a testimonial
A positive review cannot establish whether a procedure is suitable for you. A testimonial usually describes one person’s experience and may omit their diagnosis, other treatments, follow-up period or adverse effects.
Before considering exosomes and PDRN, explain your scalp symptoms, relevant medical history and current treatments to the appropriate clinician or provider. Mention previous reactions and ask what information they need to assess suitability.
For a procedure that breaks the skin, obtain a clear explanation of the practitioner’s role, product suitability, infection-control arrangements and what to do if a problem develops. Do not attempt to reproduce an injection or skin-penetrating protocol at home.
For a cosmetic product, ask for its label and instructions. “Professional use” is not a substitute for knowing what is being used.
A good consultation should also discuss alternatives, including the option of waiting for a medical diagnosis before purchasing an additional service. If the only explanation offered is that everyone benefits, the assessment is not answering your individual question.
You should not have to commit to a large package to learn the product name, method or limits of the evidence.
7. Decide what outcome would make the service worthwhile
Before comparing prices, define the problem. Are you seeking help with a diagnosed pattern of thinning, scalp discomfort, breakage or the appearance of flat roots? These are different goals.
Next, ask how the outcome will be measured. “Healthier scalp” is too broad if you are paying because you expect increased density. Cleaner-looking roots and softer hair may be worthwhile cosmetic results, but they do not demonstrate regrowth.
For exosomes and PDRN, request a realistic review point and an explanation of what happens if there is no improvement. Ask whether the recommended schedule comes from evidence for that product or simply from the package design.
Retern’s Hair Growth Solutions page can provide context for a service enquiry. Use it as a starting point for questions about the exact offering, rather than as independent proof of effectiveness.
If the cause of your hair loss remains uncertain, a medical assessment may be the more useful first investment. A fashionable ingredient does not remove the need to understand the condition being addressed.
A practical consultation example
Suppose you are shown a before-and-after photograph and told that an advanced serum “reactivates follicles.” Rather than arguing about the phrase, ask a sequence of concrete questions.
First, what diagnosis did the person in the photograph have? Second, what else did they use during the interval? Third, how much time passed between images? Fourth, does the product in their programme match the one being offered to you?
Then ask for evidence beyond the photograph. A provider may have product information but no controlled study of the complete service. That is a limitation worth knowing, rather than a detail that should be hidden.
Finally, clarify costs in writing: the initial appointment, recommended follow-up, home products and any additional procedures. Decide whether the expected benefit justifies that commitment in light of the uncertainty.
This approach lets you consider exosomes and PDRN without treating novelty as proof or assuming that all new research is worthless.
Frequently asked questions
Are exosomes and PDRN the same as PRP?
No. They are different terms for different materials. If a package includes more than one component, ask for each to be named separately. A study of a combination cannot tell you automatically how much benefit came from any individual component.
Does a high ingredient concentration guarantee a better result?
No conclusion follows from the number alone. You need to know how it was measured, what the formulation is, how it is used and whether that version was studied. A larger number on a brochure is not a substitute for relevant clinical evidence.
Is a cosmetic serum useless if the evidence is limited?
Limited evidence does not prove that a product has no effect. It means confidence in the advertised outcome is limited. The important question is whether the claims, cost and level of certainty are represented honestly so that you can make an informed choice.
Should I stop an existing hair-loss treatment to try something newer?
Discuss that with your prescriber. Do not change a medical plan simply because a product sounds more advanced. Bring the proposed product name and protocol to the discussion so that advice relates to the actual offering, not just its marketing category.
What is the most useful question to ask a provider?
Ask: “What evidence supports this exact product and method for my diagnosed condition?” Follow with questions about adverse effects, alternatives and review arrangements. A clear answer should describe both what is known and what remains uncertain.
If you contact Retern about exosomes and PDRN, bring those questions with you. The purpose of a consultation is to help you understand the offering well enough to choose, including choosing not to proceed.